Beta Bionics vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Beta Bionics (Nasdaq: BBNX) makes the iLet Bionic Pancreas, the first autonomous closed-loop insulin delivery system; reported Q1 2026 revenue of $27.6M (+57% YoY) with 24,000+ active users.
About
Beta Bionics is a commercial-stage medical device company focused on transforming the management of insulin-requiring diabetes. Its flagship product is the iLet Bionic Pancreas, a device that automates insulin delivery using a proprietary adaptive algorithm that requires no carbohydrate counting, correction boluses, or manual basal rate programming from the user — the system learns from glucose readings and autonomously adjusts insulin delivery to maintain target glucose levels. The iLet is compatible with continuous glucose monitors including Dexcom G6, Dexcom G7, and FreeStyle Libre 3 Plus.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.